Litcius/Paper detail

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Ian N Bruce, Alireza Nami, Erik Schwetje, M. Edward Pierson, Tomas Rouse, Yen Lin Chia, Denison Kuruvilla, Gabriel Abreu, Raj Tummala, Catharina Lindholm

2020The Lancet Rheumatology26 citationsDOI

Topics & Concepts

MedicinePlaceboClinical endpointPharmacokineticsPharmacodynamicsInternal medicineLupus erythematosusRandomizationAdverse effectGastroenterologyRandomized controlled trialImmunologyPathologyAntibodyAlternative medicineSystemic Lupus Erythematosus ResearchRheumatoid Arthritis Research and Therapiesinterferon and immune responses
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study | Litcius